We are live on ! Find out more
RLMD icon

Relmada Therapeutics
RLMD

87 hedge funds and large institutions have $263M invested in Relmada Therapeutics in 2021 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 36 increasing their positions, 12 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

606% more call options, than puts

Call options by funds: $5.55M | Put options by funds: $785K

200% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 12

15% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 13

2% more funds holding

Funds holding: 85 → 87 (+2)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

1.79% less ownership

Funds ownership: 59.19% → 57.4% (-1.8%)

17% less capital invested

Capital invested by funds: $316M → $263M (-$53.7M)

Holders
87
Holders Change
+2
Holders Change %
+2.35%
% of All Funds
1.52%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
15
Increased
36
Reduced
12
Closed
13
Calls
$5.55M
Puts
$785K
Net Calls
+$4.76M
Net Calls Change
-$3M

Top Buyers

1
Morgan Stanley
Morgan Stanley
New York
+$11.3M
2
Millennium Management
Millennium Management
New York
+$6.38M
3
GTC
Ghost Tree Capital
New York
+$5.35M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$3.83M
5
BBA
Baker Bros. Advisors
New York
+$3.33M

Top Sellers

1
ACA
Avoro Capital Advisors
New York
-$29.9M
2
IC
Ikarian Capital
Texas
-$7.48M
3
BlackRock
BlackRock
New York
-$6.96M
4
TA
Tiedemann Advisors
New York
-$1.78M
5
Charles Schwab
Charles Schwab
California
-$1.55M
Name Holding Trade Value Shares
Change 		Change in
Stake
TRCT
76
Tower Research Capital (TRC)
New York
$18K -$9.64K -360 -35%
PCM
77
Penserra Capital Management
California
$10K +$535 +20 +5%
PA
78
Parallel Advisors
California
$5K +$4.92K +184 New
Macquarie Group
79
Macquarie Group
Australia
$3K – – –
Daiwa Securities Group
80
Daiwa Securities Group
Japan
$1K – – –
US Bancorp
81
US Bancorp
Minnesota
$1K +$749 +28 New
GEA
82
Glen Eagle Advisors
New Jersey
$655 – – –
BBHC
83
Brown Brothers Harriman & Co
New York
$157 – – –
Nisa Investment Advisors
84
Nisa Investment Advisors
Missouri
$116 -$12.3K -458 -9%
ACA
85
Avoro Capital Advisors
New York
– -$29.9M -935,000 Closed
TA
86
Tiedemann Advisors
New York
– -$1.78M -55,556 Closed
SCM
87
Silverarc Capital Management
Massachusetts
– -$1.5K -46,729 Closed
BFM
88
Boothbay Fund Management
New York
– -$1.1M -34,353 Closed
ACM
89
ACT Capital Management
Pennsylvania
– -$791K -24,700 Closed
Jane Street
90
Jane Street
New York
– -$606K -18,919 Closed
Stifel Financial
91
Stifel Financial
Missouri
– -$281K -8,784 Closed
UBS AM
92
UBS AM
Illinois
– -$236K -7,358 Closed
CS
93
Credit Suisse
Switzerland
– -$231K -7,223 Closed
WMSA
94
Weiss Multi-Strategy Advisers
New York
– -$225K -7,043 Closed
ProShare Advisors
95
ProShare Advisors
Maryland
– -$221K -6,910 Closed
Creative Planning
96
Creative Planning
Kansas
– -$204K -6,375 Closed
CM
97
Caption Management
Oklahoma
– -$189K -5,889 Closed
SOW
98
State of Wyoming
Wyoming
– +$134 +5 New
1 2 3
4

RLMD Hedge Fund Activity: Q3 2021 in Review

87 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q3 2021, worth a combined $263M — down 17% from $316M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new RLMD positions and 13 closed out — a net gain of 2 holders — while 36 added to existing stakes and 12 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $11.3M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $29.9M sold.

  • 87 institutional investors held Relmada Therapeutics (RLMD) as of Q3 2021, up from 85 in Q2 2021.
  • Funds reported $263M of Relmada Therapeutics stock for Q3 2021, down 17% quarter-over-quarter.
  • 15 funds opened new Relmada Therapeutics positions in Q3 2021 and 13 closed out, a net change of +2 holders.
  • The largest Relmada Therapeutics buyer in Q3 2021 was Morgan Stanley, an estimated $11.3M added.
  • The largest Relmada Therapeutics seller in Q3 2021 was Avoro Capital Advisors, an estimated $29.9M sold.

Based on aggregated 13F filings for Q3 2021.